BDBM603695 US11654147, Compound 8

SMILES CN1CCN(CC1)C1CCN(CC1)c1cnc2c(cnn2c1)-c1cc(C)nc2ccccc12

InChI Key InChIKey=GVKXHJBRWOYLAK-UHFFFAOYSA-N

Data  7 IC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 7 hits for monomerid = 603695   

TargetActivin receptor type-1(Human)
The Brigham and Women'S Hospital

US Patent
LigandPNGBDBM603695(US11654147, Compound 8)
Affinity DataIC50: 5nMAssay Description:In this reporter gene cell based ALK2 and TGFβ assay, the C2Cl2 cell line was employed for the measurement of ALK2 activity, using a BRE-Luc SMA...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/26/2023
Entry Details
US Patent

TargetActivin receptor type-1(Human)
The Brigham and Women'S Hospital

US Patent
LigandPNGBDBM603695(US11654147, Compound 8)
Affinity DataIC50: 54.3nMAssay Description:In this reporter gene cell based ALK2 and TGFβ assay, the C2Cl2 cell line was employed for the measurement of ALK2 activity, using a BRE-Luc SMA...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/26/2023
Entry Details
US Patent

TargetSerine/threonine-protein kinase receptor R3(Human)
The Brigham and Women'S Hospital

US Patent
LigandPNGBDBM603695(US11654147, Compound 8)
Affinity DataIC50: 325nMAssay Description:In this reporter gene cell based ALK2 and TGFβ assay, the C2Cl2 cell line was employed for the measurement of ALK2 activity, using a BRE-Luc SMA...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/26/2023
Entry Details
US Patent

TargetActivin receptor type-1B(Human)
The Brigham and Women'S Hospital

US Patent
LigandPNGBDBM603695(US11654147, Compound 8)
Affinity DataIC50: 994nMAssay Description:In this reporter gene cell based ALK2 and TGFβ assay, the C2Cl2 cell line was employed for the measurement of ALK2 activity, using a BRE-Luc SMA...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/26/2023
Entry Details
US Patent

TargetBone morphogenetic protein receptor type-1A(Human)
The Brigham and Women'S Hospital

US Patent
LigandPNGBDBM603695(US11654147, Compound 8)
Affinity DataIC50: 1.24E+3nMAssay Description:In this reporter gene cell based ALK2 and TGFβ assay, the C2Cl2 cell line was employed for the measurement of ALK2 activity, using a BRE-Luc SMA...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/26/2023
Entry Details
US Patent

TargetBone morphogenetic protein receptor type-1B(Human)
The Brigham and Women'S Hospital

US Patent
LigandPNGBDBM603695(US11654147, Compound 8)
Affinity DataIC50: 2.40E+3nMAssay Description:In this reporter gene cell based ALK2 and TGFβ assay, the C2Cl2 cell line was employed for the measurement of ALK2 activity, using a BRE-Luc SMA...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/26/2023
Entry Details
US Patent

TargetTGF-beta receptor type-1(Human)
The Brigham and Women'S Hospital

US Patent
LigandPNGBDBM603695(US11654147, Compound 8)
Affinity DataIC50: 2.47E+3nMAssay Description:In this reporter gene cell based ALK2 and TGFβ assay, the C2Cl2 cell line was employed for the measurement of ALK2 activity, using a BRE-Luc SMA...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/26/2023
Entry Details
US Patent